Eli Lilly vs Novo Nordisk
당뇨병 및 비만 치료제를 보유한 주요 제약 그룹 vs 비만 치료 사업을 확대하고 있는 글로벌 당뇨병 치료 선도 기업. 9월 2026에 내 포트폴리오에 더 잘 맞는 종목은 무엇일까요? 아래에서 쉽게 설명합니다.
Eli Lilly has transformed into one of the most valuable pharmaceutical companies on earth, driven by its GLP-1 obesity and diabetes franchise that's reshaping how the industry thinks about blockbuster drugs, while Novo Nordisk invented the GLP-1 category and built a decades-long diabetes dominance before Lilly arrived to contest it. Both are racing to manufacture, distribute, and expand the clinical use of weight-loss treatments in a market that analysts describe as generational in size. Eli Lilly vs Novo Nordisk is the defining pharmaceutical rivalry of this decade, a head-to-head battle between two innovation machines competing for the same massive patient population.
Eli Lilly has transformed into one of the most valuable pharmaceutical companies on earth, driven by its GLP-1 obesity and diabetes franchise that's reshaping how the industry thinks about blockbuster...
주가 변동 요인
Lilly stays in focus as deal activity and GLP-1 demand keep the growth story alive.
- Lilly is drawing attention after agreeing to acquire Merida Biosciences, extending its aggressive deal-making strategy and signaling management still sees room to expand its drug pipeline beyond the current obesity and diabetes franchise.
- Investors are also weighing fresh demand signals for GLP-1 therapies, including reports that prescriptions among younger patients are rising sharply, which reinforces the long runway for the category but also keeps pricing, access, and scrutiny in focus.
- The stock remains supported by ongoing analyst optimism around incretin growth, with recent commentary framing Lilly as one of the clearest beneficiaries of continued obesity-drug adoption and international launch momentum.
Novo Nordisk is drawing attention as obesity-drug wins and pipeline setbacks collide
- Novo Nordisk’s latest catalyst is a string of obesity-drug updates, led by positive STEP Young data that showed semaglutide helped a meaningful share of children move below the obesity threshold, reinforcing the company’s leadership in the GLP-1 market.
- The company also expanded Wegovy’s footprint in Europe after launching the oral version in Germany, a sign that investors are still focused on how the pill rollout could broaden access and sharpen Novo’s competitive edge.
- Offsetting some optimism, Novo also halted two late-stage ziltivekimab trials after a low probability of success, reminding traders that the pipeline still carries execution risk even as the obesity franchise stays front and center.
Lilly stays in focus as deal activity and GLP-1 demand keep the growth story alive.
- Lilly is drawing attention after agreeing to acquire Merida Biosciences, extending its aggressive deal-making strategy and signaling management still sees room to expand its drug pipeline beyond the current obesity and diabetes franchise.
- Investors are also weighing fresh demand signals for GLP-1 therapies, including reports that prescriptions among younger patients are rising sharply, which reinforces the long runway for the category but also keeps pricing, access, and scrutiny in focus.
- The stock remains supported by ongoing analyst optimism around incretin growth, with recent commentary framing Lilly as one of the clearest beneficiaries of continued obesity-drug adoption and international launch momentum.
Novo Nordisk is drawing attention as obesity-drug wins and pipeline setbacks collide
- Novo Nordisk’s latest catalyst is a string of obesity-drug updates, led by positive STEP Young data that showed semaglutide helped a meaningful share of children move below the obesity threshold, reinforcing the company’s leadership in the GLP-1 market.
- The company also expanded Wegovy’s footprint in Europe after launching the oral version in Germany, a sign that investors are still focused on how the pill rollout could broaden access and sharpen Novo’s competitive edge.
- Offsetting some optimism, Novo also halted two late-stage ziltivekimab trials after a low probability of success, reminding traders that the pipeline still carries execution risk even as the obesity franchise stays front and center.
투자 분석
Eli Lilly
LLY
장점
- Eli Lilly dominates GLP-1 market with superior U.S. momentum in Mounjaro and Zepbound sales.
- Advanced oral GLP-1 pipeline positions it ahead in next-generation obesity treatments.
- Stronger pricing power and revenue growth outpace Novo Nordisk amid competition.
고려 사항
- Intensifying rivalry from Novo Nordisk's oral Wegovy launch erodes market share.
- Regulatory delays for oral candidates heighten execution risks in innovation race.
- Exposure to compounded semaglutide pressures margins and long-term profitability.
Novo Nordisk
NVO
장점
- Launch of oral Wegovy provides first-to-market edge in convenient GLP-1 formulations.
- Semaglutide patent upheld in China bolsters global intellectual property protection.
- Recent U.S. rollout via Amazon Pharmacy expands Wegovy accessibility and demand.
고려 사항
- Declining 2026 earnings estimates signal weakening profitability outlook.
- Intensifying GLP-1 competition from Eli Lilly hampers Ozempic and Wegovy growth.
- Pricing pressures and self-pay discounts raise concerns over margin compression.
Eli Lilly(LLY) 다음 실적 발표일
Eli Lilly’s next earnings date is expected to be October 29, 2026, before the market opens. The report will cover Q3 2026 results. This timing matches the company’s typical late-October third-quarter reporting pattern.
Novo Nordisk(NVO) 다음 실적 발표일
The next expected earnings date for NVO is November 4, 2026. The report should cover the third quarter of 2026, specifically the first three quarters of the year. This timing is consistent with Novo Nordisk’s historical pattern of releasing quarterly results in early November.
Eli Lilly(LLY) 다음 실적 발표일
Eli Lilly’s next earnings date is expected to be October 29, 2026, before the market opens. The report will cover Q3 2026 results. This timing matches the company’s typical late-October third-quarter reporting pattern.
Novo Nordisk(NVO) 다음 실적 발표일
The next expected earnings date for NVO is November 4, 2026. The report should cover the third quarter of 2026, specifically the first three quarters of the year. This timing is consistent with Novo Nordisk’s historical pattern of releasing quarterly results in early November.
Nemo에서 LLY 또는 NVO 매수하기
수수료 무료
주식, ETF 등을 수수료 없이 거래하세요. 수익을 더 많이 지키세요.
신뢰할 수 있는 규제 기관 인가
2015년부터 Exinity Group의 일원으로, 전 세계 100만 명 이상의 고객에게 서비스를 제공합니다.
현금 예치금 6% 이자
투자하지 않은 현금에 연 6%(AER) 이자를 매일 지급합니다.
